Open Label Phase 2 Study of the Safety and Biological Activity of GCS-100 in Subjects With Chronic Lymphocytic Leukemia.

Trial Profile

Open Label Phase 2 Study of the Safety and Biological Activity of GCS-100 in Subjects With Chronic Lymphocytic Leukemia.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2013

At a glance

  • Drugs GCS 100 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Most Recent Events

    • 25 Jan 2012 Status changed from suspended to discontinued.
    • 20 May 2009 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
    • 20 Oct 2008 Trial phase changed from I to II as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top